Form 4: Sutro Biopharma CEO Boosts Stake with New Equity Grants

Sutro Biopharma's CEO and Director, Jane Chung, reported significant equity transactions including the vesting of restricted stock units and new grants of RSUs and stock options.

Summary

• Jane Chung, CEO and Director of Sutro Biopharma, reported multiple equity transactions on March 1 and March 2, 2026.
• Transactions included the acquisition of 688, 2,500, and 7,750 shares of common stock upon the vesting of previously granted Restricted Stock Units (RSUs).
• A total of 4,050 shares were disposed of to cover income tax withholding obligations related to the RSU settlements, at prices of $20.47 and $20.55 per share.
• Chung received a new grant of 40,000 Restricted Stock Units (RSUs) on March 2, 2026, which will vest 1/4 annually starting March 1, 2027.
• Additionally, Chung was granted 175,000 stock options on March 2, 2026, with an exercise price of $20.55, vesting monthly over 48 months starting April 1, 2026.
• Following these transactions, Chung's direct beneficial ownership of common stock increased to 20,779 shares, along with 40,000 RSUs and 175,000 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting continued executive commitment and standard long-term incentive compensation, which aligns management interests with shareholder value.

Positives

• Significant new equity grants (40,000 RSUs and 175,000 stock options) demonstrate continued commitment and alignment of interests with shareholders.
• The vesting of previously granted RSUs indicates the achievement of prior performance or service conditions.
• Increased beneficial ownership of common stock (from 14,579 to 20,779 shares directly owned after transactions, plus new derivative holdings).

Negatives

• Disposal of 4,050 shares of common stock to cover tax withholding obligations, which is a standard practice but reduces direct share count.

Future Outlook

The vesting schedules for the newly granted RSUs and stock options extend through March 2030 and March 2036, respectively, indicating a long-term incentive structure for the CEO.

Industry Context

StockSavvy.ai notes that equity grants to executive leadership, particularly in the biotechnology sector, are a common practice to align management incentives with long-term shareholder value creation and retain key talent. The significant new grants to CEO Jane Chung reflect ongoing confidence in her leadership and the company's future prospects.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of these equity grants, involving both Restricted Stock Units and stock options with multi-year vesting schedules, is consistent with compensation practices seen in comparable biotechnology companies.
• For instance, similar long-term incentive plans are often utilized by companies like Moderna (MRNA) or BioNTech (BNTX) to incentivize executives over extended periods, linking compensation directly to company performance and stock appreciation.
• The exercise price of $20.55 for the options is at market price, which is standard for new grants.

Stakeholder Impact

• Shareholders: The new equity grants align the CEO's long-term interests with shareholder value creation, potentially fostering sustained growth and performance.
• Employees: May signal stability in leadership and a commitment to long-term strategic goals.

Next Steps

• Continued service by Jane Chung to meet vesting conditions for RSUs and stock options.
• Future vesting events for 40,000 RSUs annually starting March 1, 2027.
• Future vesting events for 175,000 stock options monthly starting April 1, 2026.

Key Dates

Recommendation

The filing details routine executive compensation events, including RSU vestings and new equity grants, which are standard practice for aligning management incentives. While the new grants are a positive sign of continued commitment, they do not present new fundamental information that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while monitoring future company performance and broader market conditions.

Keywords

Sutro Biopharma, STRO, Jane Chung, CEO, Director, Form 4, SEC filing, insider transaction, equity grant, restricted stock units, RSUs, stock options, vesting, beneficial ownership